Guidelines: Difference between revisions

From UrologySchool.com
Jump to navigation Jump to search
Line 82: Line 82:
*Non-muscle Invasive Bladder Cancer (2024 Amendment)
*Non-muscle Invasive Bladder Cancer (2024 Amendment)
*Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
*Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
*Management of LUTS attributed to BPH (2023)
*Management of LUTS attributed to BPH (2023 Amendment)
*Interstitial Cystitis/Bladder Pain Syndrome (2022)
*Interstitial Cystitis/Bladder Pain Syndrome (2022)
*[[AUA: Neurogenic LUTD (2021)|Neurogenic LUTD (2021)]]
*[[AUA: Neurogenic LUTD (2021)|Neurogenic LUTD (2021)]]

Revision as of 15:35, 3 August 2024

AUA Guidelines

Oncology

Prostate

Bladder

Kidney

Testicular

Upper Tract Urothelial Carcinoma

Non-oncology

Andrology

Functional

Infertility

Infections and Inflammation

Pediatrics

Stones

Other

Contribute

  • Overactive Bladder (2024)
  • Incontinence after Prostate Therapy (2024 Amendment)
  • Non-muscle Invasive Bladder Cancer (2024 Amendment)
  • Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
  • Management of LUTS attributed to BPH (2023 Amendment)
  • Interstitial Cystitis/Bladder Pain Syndrome (2022)
  • Neurogenic LUTD (2021)
  • Disorders of ejaculation (2020)
  • Antibiotic Prophylaxis (2019)

CUA Guidelines

Oncology

Prostate

Bladder

Kidney

Non-oncology

Andrology

Functional

Infections and Inflammation

Infertility

Pediatrics

Stones

Other

Contribute

  • Ureteral calculi (2022)
  • Pediatric bladder dysfunction (2021)
  • Sporadic angiomyolipomas (2020)
  • Male urethral stricture (2020)
  • Catheter use (2020)
  • Renal mass biopsy (2019)
  • Pheochromocytoma surveillance (2019)
  • Pediatric hemorrhagic cystitis (2019)